Lack of Correlation between Plasma Neuropeptide Y and Typical and Atypical Febrile Seizures

  • Abolfazl Mahyar Mail Department of Pediatrics, Qazvin University of Medical Sciences, Qazvin, Iran.
  • Parviz Ayazi Department of Pediatrics, Qazvin University of Medical Sciences, Qazvin, Iran.
  • Mohsen Nazari Department of Pediatrics, Qazvin University of Medical Sciences, Qazvin, Iran.
  • Hamid Reza Sarokhani Department of Laboratory Sciences, Qazvin University of Medical Sciences, Qazvin, Iran.
  • Mohammad Mahdi Daneshi-Kohan Department of Laboratory Sciences, Qazvin University of Medical Sciences, Qazvin, Iran.
  • Amir Javadi Department of Biostatics, Qazvin University of Medical Sciences, Qazvin, Iran.
Keywords:
Febrile seizures, Neuropeptide Y

Abstract

It is known that neuropeptide Y which is widely distributed throughout the central nervous system is able to prevent seizures in animals. There are limited studies about the role of neuropeptide Y in febrile seizures. This study was conducted to evaluate the association between plasma neuropeptide Y level and febrile seizures in children. Seventy six patients with typical and atypical febrile seizures (each group 38 patients) and 38 sex and age matched control subjects were enrolled. The mean plasma levels of neuropeptide Y in typical and atypical febrile seizures were 90.60±28.01 and 97.34±41.27 pmol/l respectively. This value in control group was 88.94±32.66 pmol/l. There was no significant differences between groups regarding plasma neuropeptide Y level (P=0.532). Also, there was no significant difference in comparison with case groups (P=0.40). This study revealed that there is no association between plasma neuropeptide Y and febrile seizures.

References

Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics. Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures. Pediatrics 2008;121(6):1281-6

Sholomo S. Febrile seizures. In: Swaiman KF, Ashwal S, Ferriero DM, editors. Pediatric neurology: principles and practice. 4th ed. Philadelphia: Mosby, 2006:1079-86.

Mikati MA M. Febrile seizure. In:KliegmanRM,Stanton BF,St.Geme JW, Schor NF,Behrman RE. Nelson textbook of pediatrics. 19th ed. Philadelphia: Saunders, 2012:2017-9.

Mahyar A, Ayazi P, Fallahi M, Javadi A.Correlation between serum selenium level and febrile seizures. Pediatr Neurol 2010;43(5):331-4

Mahyar A, Ayazi P, Fallahi M, Javadi A. Risk factors of the first febrile seizures in Iranian children. Int J Pediatr 2010;2010:862897.

Lin LC, Lee WT, Chen IJ, Yang RC. Lower plasma neuropeptide level in patients with atypical febrile convulsions, Kaohsiung J Med Sci 2010;26(1):8-12.

Lin LC, Lin HS, Yang RC. Neuropeptide gene polyamorphism and plasma neuropeptide level in febrile seizure patients in taiwan, Kaohsiung J Med Sci 2007;23(11):560-4.

William F. Colmers DRN, Bouchaïb E B. Neuropeptide Y and Epilepsy. Epilepsy Curr 2003;3(2):53–8.

Wu G, Feder A, Wegener G, Bailey C, Saxena S, Charney D, Mathé AA. Central functions of neuropeptide Y in mood and anxiety disorders. Expert Opin Ther Targets 2011;15(11):1317-31

Woldbye DP, Larsen PJ, Mikkelsen JD, Klemp K, Madsen TM, Bolwig TG. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nat Med 1997;3(7):761–4.

Dubé C, Brunson KL, Eghbal-Ahmadi M, Gonzalez-Vega R, Baram TZ. Endogenous neuropeptide Y prevents recurrence of experimental febrile seizures by increasing seizure threshold. J Mol Neurosci 2005;25(3):275–83.

Benarroch EE. Neuropeptide Y its multiple effects in the CNS and potential clinical significance. Neurology 2009;72(11):1016-20

Noè F, Pool AH, Nissinen J, Gobbi M, Bland R, Rizzi M, Balducci C, Ferraguti F, Sperk G, During MJ, Pitkänen A, Vezzani A. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 2008;131(Pt 6):1506–15.

Klapstein GJ ,Colmers WF. On the sites of presynaptic inhibition by neuropeptide Y in rat hippocampus in vitro. Hippocampus 1993;3(1):10-11.

Vezzani A, Civenni G, Rizzi M, Monno A, Messali S,Samanin R. Enhanced neuropeptide Y release in the hippocampus is associated with chronic seizure susceptibility in kainic acid treated rats. Brain Res 1994;660(1):138-43.

Vizzani A, Sperk G, Colmers WF. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci 1999;22(1):25–30.

Patrylo PR, van den Pol AN, Spencer DD, Williamson A. NPY inhibits glutamatergic excitation in the epileptic human dentate gyrus. J Neurophysiol 1999;82(1):478–83.

Smiałowska M, Bijak M, Sopala M, Tokarski K. Inhibitory effect of NPY on the picrotoxin-induced activity in the hippocampus: a behavioural and electrophysiological study. Neuropeptides 1996;30(1):7-12.

Furtinger S, Pirker S, Czech T, Baumgartner C, Ransmayr G, Sperk G. Plasticity of Y1 and Y2 receptors and neuropeptide Y fibers in patients with temporal lobe epilepsy. J Neurosci 2001;21(15):5804–12.

How to Cite
1.
Mahyar A, Ayazi P, Nazari M, Sarokhani HR, Daneshi-Kohan MM, Javadi A. Lack of Correlation between Plasma Neuropeptide Y and Typical and Atypical Febrile Seizures. Acta Med Iran. 51(4):246-249.
QRcode
Section
Articles